Literature DB >> 6395952

Inhibition of ribonucleotide reductase by caracemide.

E C Moore, T L Loo.   

Abstract

Caracemide, a new antitumor agent now in clinical trial, was tested against partially purified ribonucleotide reductase from rat Novikoff tumor. It was found to be an active inhibitor, about one-ninth as effective as hydroxyurea.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6395952

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  4 in total

1.  Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.

Authors:  T Lad; J Schor; M Mullane; R Carroll; D Chernicoff; R Blough; L Weidner
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

2.  Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.

Authors:  Nicholas O Roman; Betty K Samulitis; Lee Wisner; Terry H Landowski; Robert T Dorr
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-26       Impact factor: 3.333

3.  Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion.

Authors:  R Pazdur; G G Chabot; L H Baker
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

Review 4.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.